A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
A phase 3 trial testing Emactuzumab, active and no longer recruiting.
Overview
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study is a phase 3 interventional study registered as NCT03768063, led by Hoffmann-La Roche, and active but no longer recruiting when checked on 2026-09-11. Official title: An Open Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella B). Planned enrolment is 1000 participants (estimated). The study started in 2019-02-28 and primary completion is expected in 2028-07-05. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialStudy of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)
Shares Emactuzumab and the tag ctgov-ingest.
- TrialA Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
Shares Roche / Genentech and the tag ctgov-ingest.
- TrialCevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Shares Roche / Genentech and the tag ctgov-ingest.
- TrialRO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
Shares Roche / Genentech and the tag ctgov-ingest.
- TreatmentEnglumafusp alfa
Shares Roche / Genentech and the tag ctgov-ingest.
- TreatmentADG126
Shares Roche / Genentech and the tag ctgov-ingest.
- TreatmentCevostamab
Shares Roche / Genentech and the tag ctgov-ingest.
- TreatmentRO7771950
Shares Roche / Genentech and the tag ctgov-ingest.